Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden
(2011) In Nordic Journal of Psychiatry 65(1). p.40-46- Abstract
- Introduction: The aim of the present study was to obtain point prevalence estimates of the metabolic syndrome according to the NCEP III criteria in a sample of patients with schizophrenia spectrum disorders treated with atypical antipsychotic drugs in Denmark and Sweden, and to assess the psychiatrists' choice of recommendations for follow-up interventions based on the patients' laboratory results. Method: This was a cross-sectional, observational multi-center study in Denmark and Sweden, in consecutively screened in- and outpatients with schizophrenia spectrum disorders and continuously treated for at least 3 months with atypical antipsychotic drugs. Results: The metabolic syndrome as per medical history was present in 1% of 582 evaluable... (More)
- Introduction: The aim of the present study was to obtain point prevalence estimates of the metabolic syndrome according to the NCEP III criteria in a sample of patients with schizophrenia spectrum disorders treated with atypical antipsychotic drugs in Denmark and Sweden, and to assess the psychiatrists' choice of recommendations for follow-up interventions based on the patients' laboratory results. Method: This was a cross-sectional, observational multi-center study in Denmark and Sweden, in consecutively screened in- and outpatients with schizophrenia spectrum disorders and continuously treated for at least 3 months with atypical antipsychotic drugs. Results: The metabolic syndrome as per medical history was present in 1% of 582 evaluable patients at baseline. After performing laboratory measurements and applying the NCEP III criteria, metabolic syndrome was confirmed in 43% of subjects. The high rate of metabolic syndrome did not elicit much decisive action on the part of the treating psychiatrists; the most frequent action taken was dietary and exercise advice (in 75% of subjects), while in 54% and 19% of subjects a laboratory follow-up and blood pressure follow-up were advised respectively. Change of antipsychotic medication was recommended in only 10% of patients, and in further 11% of patients, no action was taken. Conclusion: Observed metabolic syndrome prevalence rates were at least twice the rates observed in a normal, non-diabetic population. It appears that in this vulnerable population of patients with schizophrenia spectrum disorders, metabolic syndrome remains underdiagnosed and undertreated. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1868940
- author
- Larsen, John Teilmann ; Fagerquist, Maria ; Holdrup, Mette ; Christensen, Bjarne ; Sigalin, Catarina and Nilsson, Peter LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Interventions, Metabolic syndrome, Prevalence, Schizophrenia
- in
- Nordic Journal of Psychiatry
- volume
- 65
- issue
- 1
- pages
- 40 - 46
- publisher
- Informa Healthcare
- external identifiers
-
- wos:000286683100008
- scopus:78751519432
- pmid:20482460
- ISSN
- 1502-4725
- DOI
- 10.3109/08039488.2010.486443
- language
- English
- LU publication?
- yes
- id
- 8df2e301-058f-4846-b29b-63de5dfe95ae (old id 1868940)
- date added to LUP
- 2016-04-01 09:48:23
- date last changed
- 2025-04-04 14:08:36
@article{8df2e301-058f-4846-b29b-63de5dfe95ae,
abstract = {{Introduction: The aim of the present study was to obtain point prevalence estimates of the metabolic syndrome according to the NCEP III criteria in a sample of patients with schizophrenia spectrum disorders treated with atypical antipsychotic drugs in Denmark and Sweden, and to assess the psychiatrists' choice of recommendations for follow-up interventions based on the patients' laboratory results. Method: This was a cross-sectional, observational multi-center study in Denmark and Sweden, in consecutively screened in- and outpatients with schizophrenia spectrum disorders and continuously treated for at least 3 months with atypical antipsychotic drugs. Results: The metabolic syndrome as per medical history was present in 1% of 582 evaluable patients at baseline. After performing laboratory measurements and applying the NCEP III criteria, metabolic syndrome was confirmed in 43% of subjects. The high rate of metabolic syndrome did not elicit much decisive action on the part of the treating psychiatrists; the most frequent action taken was dietary and exercise advice (in 75% of subjects), while in 54% and 19% of subjects a laboratory follow-up and blood pressure follow-up were advised respectively. Change of antipsychotic medication was recommended in only 10% of patients, and in further 11% of patients, no action was taken. Conclusion: Observed metabolic syndrome prevalence rates were at least twice the rates observed in a normal, non-diabetic population. It appears that in this vulnerable population of patients with schizophrenia spectrum disorders, metabolic syndrome remains underdiagnosed and undertreated.}},
author = {{Larsen, John Teilmann and Fagerquist, Maria and Holdrup, Mette and Christensen, Bjarne and Sigalin, Catarina and Nilsson, Peter}},
issn = {{1502-4725}},
keywords = {{Interventions; Metabolic syndrome; Prevalence; Schizophrenia}},
language = {{eng}},
number = {{1}},
pages = {{40--46}},
publisher = {{Informa Healthcare}},
series = {{Nordic Journal of Psychiatry}},
title = {{Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden}},
url = {{http://dx.doi.org/10.3109/08039488.2010.486443}},
doi = {{10.3109/08039488.2010.486443}},
volume = {{65}},
year = {{2011}},
}